Drug Index

Hydromorphone

 
print

Mechanism :

Binds to opioid receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; causes cough suppression by direct central action in the medulla; produces generalized CNS depression.


Indication :

• Pain management: Reserve for use in patients for whom alternative treatment options (e.g., non-opioid analgesics, opioid combination products) are ineffective.


Contraindications :

Hypersensitivity (e.g., anaphylaxis) to hydromorphone, hydromorphone salts, or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment or ventilatory support; gastrointestinal obstruction, including paralytic ileus.


Dosing :

Oral:

Children: 0.03-0.08 mg/kg/dose PO every 4-6 hours, not to exceed 5 mg/dose.

Adolescents: 1-4 mg/dose PO every 4-6 hours.

Injectable:

Children: 0.015 mg/kg IV every 4-6 hours.

Adolescents: 1-2 mg/dose IV/IM/SC every 4-6 hours.


Adverse Effect :

Dry mouth, palpitation, tachycardia, urinary retention, angina pectoris, bradycardia, cardiac arrest, circulatory depression, myocardial infarction, QT-interval prolongation, severe cardiac arrhythmias, shock, ST-segment elevation, syncope, ventricular tachycardia, agitation, coma, dizziness, dysphoria, mental clouding or depression, euphoria, faintness, nervousness, restlessness, sedation, seizures, visual disturbances, weakness, constipation, nausea, vomiting, anorexia, abdominal distention, biliary tract spasm, decreased appetite, decreased intestinal motility, gastroesophageal reflux disease, paralytic ileus, respiratory depression, respiratory arrest, hypoxia, bronchospasm, dyspnea, rhinorrhea, flu-like symptoms, flushing, pruritus, sweating, urticaria, skin rash, hyperhidrosis, warmness of face/neck/upper thorax.


Interaction :

Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan.
Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.
Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine.
CNS Depressants: May enhance the CNS depressant effect of Opioid Analgesics.
Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.
Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.


07/18/2019 01:55:47 Hydromorphone
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0